Human placental lactogen (hPL) model for the normal pregnancy

This study includes 75 females with normal pregnancies, and presents individual cases of longitudinal series of human placental lactogen (hPL). Samples for hPL levels are taken during the period from gestational week 26 and until labour. A modified Gompertz equation is defined, characterized as growth at a continuously decreasing exponential rate, which finally plateaus in gestational week 36. This modified Gompertz equation adequately fitted individual hPL series. The work describes that a final hPL forecast for the normal pregnancy could be obtained in gestational week 30 using knowledge on maternal height and age, combined with a single hPL sample. The present model was applied in six pathological pregnancies with intrauterine growth retardation, and in all cases measured hPL levels were below the model estimate.

Transplantable rat choriocarcinoma cells express placental lactogen: identification of placental lactogen-I immunoreactive protein and messenger ribonucleic acid

The purpose of this investigation was to evaluate the abilities of a transplantable rat choriocarcinoma (Rcho) to produce placental PRLs. The Rcho tumor was analyzed biochemically and histologically for the expression of placental PRLs. Expression of placental PRL mRNAs was determined by Northern blot and in situ hybridization analyses. Expression of placental PRL proteins was determined by Western blot and immunocytochemical analyses. Histologically, Rcho tumors were characterized by the appearance of giant cell surrounding hemorrhagic regions. Female rats bearing the Rcho tumor beneath their kidney capsule showed extensive mammary gland development. The Rcho tumors expressed placental lactogen-I (PL-I) mRNA and protein, but there was no evidence of placental lactogen-II (PL-II), PRL-like protein-A (PLP-A), or PRL-like protein-B (PLP-B). Rcho PL-I mRNA and proteins migrated as a 1-kilobase species and a 36- to 40-kDa species similar to those expressed by normal rat trophoblast tissues. The cell type responsible for Rcho PL-I production was the giant cell, similar to that observed in normal rat trophoblast tissues. In summary, we have demonstrated the production of PL-I by a transplantable rat choriocarcinoma (Rcho). The Rcho tumor resembles rat trophoblast tissue at early postimplantation stages (days 6-10 of gestation) and may be a useful tool for studying placental PRL expression during trophoblast differentiation.

Inhibition of aromatase activity by 8-bromo-cyclic adenosine monophosphate in cultured first-trimester human trophoblast

We have previously shown that 8-bromo-adenosine-3':5'-cyclic monophosphate inhibits production of estradiol from androgen precursors in trophoblast isolated from term placentas. In these experiments we sought to evaluate the effect of 8-bromo-adenosine-3':5'-cyclic monophosphate on aromatase activity in first-trimester trophoblast culture. Trophoblast cells were enzyme dispersed from first-trimester placentas and purified on a Percoll gradient. On the third and fourth day after dispersion cultures were treated with androstenedione or testosterone with and without 2 mmol/L 8-bromo-adenosine-3':5'-cyclic monophosphate. The quantity of estradiol, estrone, progesterone, human placental lactogen, and human chorionic gonadotropin was determined by radioimmunoassay. We concluded that in first-trimester trophoblast, as previously reported in term trophoblast, 8-bromo-adenosine-3':5'-cyclic monophosphate inhibited the production of estradiol from the supplied androgen precursors. Human chorionic gonadotropin and human placental lactogen production was stimulated by 8-bromo-adenosine-3':5'-cyclic monophosphate. Progesterone production was either stimulated or was unchanged by the presence of 8-bromo-adenosine-3':5'-cyclic monophosphate.

Ontogeny of placental lactogen-I and placental lactogen-II expression in the developing rat placenta

The purpose of this investigation was to identify the cellular origin, and the temporal and regional characteristics of placental lactogen-I (PL-I) and placental lactogen-II (PL-II) expression during placental development in the rat. PL-I and PL-II mRNA expression were assessed by Northern blot analysis and in situ hybridization. PL-I and PL-II protein expression were determined by Western blot and immunocytochemical analyses. PL-I mRNA was first detected by in situ hybridization at Day 6 of gestation in mural trophoblast giant cells and a day later, PL-I protein was first detected by immunocytochemistry. PL-I immunostaining extended to the polar trophoblast giant cells as gestation advanced. Polar trophoblast giant cell staining for PL-I was not as intense as the mural trophoblast giant cell staining. Northern and Western blot analyses confirmed the asymmetric distribution of PL-I expression. PL-I mRNA migrated as a 1-kb species and PL-I protein migrated as 30- and 36-40-kDa forms. PL-I expression abruptly declined at Day 12, and by Day 13, PL-I was not detectable. PL-II protein was first detectable at Day 11 of gestation and was localized to trophoblast giant cells. PL-II mRNA could be detected at Day 10 of gestation. Northern and Western blot analyses indicated that PL-II expression significantly increased as gestation advanced and that PL-II expression was asymmetrically distributed similar to PL-I. PL-II mRNA migrated as a 1-kb species and PL-II protein migrated as a 25-kDa species. Blastocysts recovered on Day 4 of gestation initially showed no detectable expression of PL-I or PL-II; however, after 2 days of culture PL-I protein expression was detectable. Biochemical characteristics of PL-I synthesized and secreted by blastocyst outgrowths were similar to PL-I synthesized and secreted by Day 10 placental explants. In summary, (1) PL-I and PL-II are produced by trophoblast giant cells of the developing placenta, (2) PL-I and PL-II exhibit distinct temporal and regional patterns of expression during placental morphogenesis, and (3) PL-I expression by blastocyst outgrowths can be induced in vitro, whereas a more complex array of signals appears necessary for induction of PL-II expression.

A serum-free system for culturing human placental trophoblasts

We have compared hormone production by early gestation and term human placental trophoblasts cultured in Ham's F10 medium containing 10% fetal bovine serum with that by cells cultured in serum-free HB102 medium. Mean daily production of progesterone on Days 3 to 7 was approximately 25% less by both early gestation and term cells cultured in HB102 as compared to Ham's F10, but production was maintained at a stable level for at least 7 d longer than the cells in Ham's. Estradiol production from 10(-6) M dehydroepiandrosterone by both early gestation and term cells was comparable in both media. Human placental lactogen production on Days 3 to 7 was 40% less by cells cultured in HB102. Human chorionic gonadotropin (hCG) output by early gestation cells was also 50% less in HB102 but term cells in HB102 produced twice as much hCG as those in Ham's F10. 3B-Hydroxysteroid dehydrogenase (3BHSD) activity in early gestation and term cells and 11B-hydroxysteroid dehydrogenase (11BHSD) activity of early gestation cultures was comparable in the two media. 11BHSD activity was decreased in the term cultures, and this decrease was more marked in Ham's than in HB102. Sulfatase and aromatase activities in the early gestation cultures were comparable in both media; sulfatase activity was comparable and aromatase activity only 20% less in the term cells cultured in HB102. These results indicate that serum-free HB102 supports differentiated function of human trophoblast cells and is useful for studies of placental activity for as long as 14 d in culture.

Synthesis and secretion of ovine placental lactogen and its biochemical properties

The biochemical properties of ovine placental lactogen (oPL) have been previously determined following purification, which has yielded various results. To clarify the properties of oPL prior to purification, oPL was examined in solubilized fetal cotyledonary tissue (d 100 of gestation) or conditioned culture medium by electrophoretic, immunoblotting and immunoprecipitation techniques. In cotyledonary tissue or conditioned culture medium, oPL has an apparent molecular weight (Mr) of 22,000 with an isoelectric point (pI) of 9.2. Incorporation of [3H]-glucosamine or [3H]-mannose into immunoreactive oPL could not be detected, nor did the presence of tunicamycin in explant culture medium alter the apparent Mr of oPL. In vitro translation of d 100 fetal cotyledonary mRNA, followed by immunoprecipitation, provided evidence that pre-oPL has an apparent Mr of 25,000. The size of oPL mRNA was determined to be approximately 1,350 base pairs by Northern hybridization procedures using an oligonucleotide probe which was generated from oPL amino acid sequence data. These experiments suggest that the only intracellular processing oPL undergoes is removal of a amino-terminal signal sequence. We conclude that oPL is synthesized and secreted as a single nonglycosylated-basic protein, at a time during gestation when circulating oPL is elevated.

Differential control of placental lactogen release and progesterone production by ovine placental tissue in vitro

The hypothesis that placental secretion of progesterone (P4) and ovine placental lactogen (oPL) are controlled through different mechanisms was tested. Placental tissue was obtained at days 133-138 of pregnancy, and explant incubations were established using 200 mg tissue per flask in 5 ml O2-saturated DMEM containing 24 mM HEPES and lacking phenol red (pH 7.4). Following a 30-min preincubation, and a 15-min control period, test substances were added and incubations continued, with periodic gassing, for 4 h at 37 degrees C in a shaking water bath. Dopamine (DA), norepinephrine (NE) and epinephrine significantly stimulated P4 production (P less than 0.05). The enhancement of placental P4 production was mimicked by the addition of 8-bromo-cyclic adenosine monophosphate and forskolin (P less than 0.05). The response to catecholamines was abolished by the addition of propranolol (P less than 0.05) but not by phentolamine (P greater than 0.05). Inclusion of a membrane-permeant substrate for P4 synthesis, 25-hydroxycholesterol, increased basal (P less than 0.05) but did not enhance agonist-induced P4 production (P greater than 0.05). High performance liquid chromatographic analysis of placental tissue demonstrated the presence of DA (80.8 +/- 7.07 pg/mg) and NE (48.8 +/- 5.77 pg/mg), as well as catecholamine metabolites. Addition of 1,2-dioctanoyl-sn-glycerol (DAG) or phorbol 12-myristate-13-acetate (PMA) enhanced oPL secretion (P less than 0.05) without affecting P4 production. The response to DAG and PMA, representing the release of considerably more oPL than can be detected by extracting the tissue, was not influenced by treatment with cycloheximide (P greater than 0.05) indicating that secretion of preformed oPL is regulated by the protein kinase C pathway. These results support the hypothesis that the secretion of oPL and the production of P4 are controlled by different mechanisms.

Production of mouse placental lactogen-I by trophoblast giant cells in utero and in vitro

Mouse placental lactogen-I (mPL-I) is the earliest appearing member of the PRL-GH family of placental hormones. Using immunological techniques, we have localized mPL-I both in utero and in vitro to trophoblast giant cells. Detectable amounts of mPL-I were first seen by immunohistochemistry on day 6 of gestation in the mural trophoblast. On day 7 giant cells of the ectoplacental cone also contained mPL-I, and on day 10 giant cells adjacent to both the decidua basalis and decidua capsularis stained positive. By day 12 however, all intra- and extraembryonic tissues were negative. The pattern of mPL-I staining in the placenta is consistent with its reported gestational serum profile. mPL-I was also present in trophoblast giant cells in vitro shortly after attachment and spreading of day 5 blastocysts. Analysis of conditioned medium from blastocyst outgrowths by immunoprecipitation and two-dimensional electrophoresis, and by immunoblotting, identified mPL-I as the major secretory product from the trophoblast, consisting of a group of acidic proteins of 30,000-45,000 Mr. The synthesis and secretion of mPL-I in vitro occurred in a serum-free medium suggesting that production of this hormone is part of an endogenous program of trophoblast differentiation.

Immunocytochemical localization and messenger ribonucleic acid concentrations for human placental lactogen in amnion, chorion, decidua, and placenta

Human placental lactogen is one of the major hormones secreted by the placental syncytiotrophoblast and detected in the maternal circulation. Other sources of this hormone in intrauterine tissues at term have been sought by means of immunohistochemistry and northern analysis. Avidin-biotin immunoperoxidase staining with a specific polyclonal antibody to human placental lactogen showed this hormone to be present in groups of cells at the interface between chorionic cytotrophoblast and decidua parietalis and in some cells of the basal plate in addition to the classic source, the syncytiotrophoblast. Hybridization of polyadenylic-(+)ribonucleic acid extracted from amnion, chorion, decidua parietalis, basal plate, and placental trophoblast with a radiolabeled 48 mer oligonucleotide and a 540 base pair complementary deoxyribonucleic acid probe to human placental lactogen showed the placental trophoblast to be the major source of human placental lactogen and the extravillous chorion and basal plate to be additional minor sources.

Modulators of cyclic AMP metabolism induce syncytiotrophoblast formation in vitro

During placental development cytotrophoblast stem cells fuse to form the syncytiotrophoblast, a multinucleate cytoplasm with a brush border in contact with the maternal blood. Biochemical differentiation including the expression of placental-specific proteins and hormones accompanies this maturation. However, the biochemical mechanisms responsible for these events are unknown. We have defined a system in which single cytotrophoblast-like cells of the human choriocarcinoma (BeWo) cell line undergo fusion and extensive morphological differentiation following their treatment with effectors of cyclic AMP metabolism. Forskolin incubation caused a dose-dependent increase in intracellular and secreted cyclic AMP and a coordinate fusion of cells which yielded syncytia containing hundreds of nuclei per cytoplasm and a mature dense "placental-like" brush border. These fused cells also synthesized and secreted large amounts of both subunits of chorionic gonadotropin. However, they continued to synthesize several other placenta-specific proteins--placental-like alkaline phosphatase, placental lactogen, and SP1--at rates similar to those in control cells. Other reported effectors of cyclic AMP metabolism also induced cell fusion, although theophylline, an inhibitor of phosphodiesterase, induced fusion by a cyclic AMP-independent mechanism. Additionally, unlike the case with forskolin, treatment of BeWo cells with theophylline did not induce other morphological features of mature syncytiotrophoblasts. Thus, this system will allow one to examine the biochemical mechanism of placental cell fusion in the absence of other variables of cell differentiation.

Human placental lactogenic hormone as a parameter for placental function in renal transplanted women

In 13 pregnant women with renal transplants the serum concentration of placental hormones were determined in order to show their ability to predict fetal problems especially placental insufficiency. It is shown that the hPL values were increased because of reduced elimination of hPL, presumably in the renal tubuli. In this study the weight of only one newborn was over the 50th percentile in spite of the fact that all but one had hPL values over the 50th percentile and in even 8 pregnancies the values were over the 95th percentile. In most of the growth-retarded fetus's the ratio between hPL and the weight of the newborns was more complex. It is concluded that in renal transplanted pregnant women, hPL as a parameter for the placental function must be used with reservation and is not able to predict placental insufficiency.

Characterization of the synthetic capacities of isolated placental binucleate cells from sheep and goats

Sheep and goat binucleate cells (BNC) play a central role in placental growth and development. This study reports a simple method for isolating 60-70% pure populations of BNC of high viability. After incubation of the isolated BNC with a brief pulse of 14C-leucine or 3H-fucose or 3H-galactose, electron microscope autoradiography showed that label was eventually incorporated into the characteristic BNC granules via the Golgi body. Fucose and galactose initially showed a much higher Golgi body label than leucine, which was at first predominantly localised in the endoplasmic reticulum. 35S-methionine incorporation by BNC suspensions was extensive enough to allow an immunoprecipitation investigation which demonstrated that the protein hormone ovine placental lactogen and the SBU-3 antigen were synthesised de novo. Previous studies with isolated BNC have shown a remarkable range of substances to be released into the incubation medium but not necessarily synthesised during the incubation. The results demonstrate unequivocally that isolated BNC's are capable of total synthesis in vitro of two of the proteins that these same cells are known to secrete in vivo.

Simultaneous autoradiography and line immunoelectrophoresis (ARLIE): a novel combination to identify de novo protein synthesis by pregnancy tissues

A novel combination of two conventional techniques (autoradiography, AR and line immunoelectrophoresis, LIE; ARLIE) for identification of specific proteins synthesized de novo by explants is described. The incorporation rate of [35S]-methionine was linear in proteins derived from cytosol fractions and supernatants of first trimester human trophoblast and gestational endometrium for up to 18 h. SDS-PAGE analysis of these fractions provided further evidence of the protein synthesis and secretion by the tissue explants. The ARLIE system was evaluated by investigating the synthesis and secretion of five test proteins (PP12, PP14, hPL, FA-1 and FA-2) by trophoblast and gestational endometrium. The synthesis P12 and PP14 could be demonstrated by gestational endometrium only. Similarly the synthesis of hPL could be demonstrated by the trophoblast alone. The synthesis of the fetal proteins (FA-1 and FA-2) could not be demonstrated by either tissue. The control procedure, Protein A assisted immunoprecipitation, yielded similar results for PP14 but not hPL. This novel combination (ARLIE) provides a simple technique with which to study the de novo synthesis of several proteins simultaneously which is independent of the subclass and species of origin of antibodies.

Human chorionic somatomammotropin gene expression in primary placental cell cultures

Mono-nucleated cytotrophoblasts (cytoTBs) were prepared by Percoll gradient fractionation of enzymically disaggregated human placental tissue. These cells were plated in monolayer culture in the presence of fetal calf and calf serum. Within 2-24 h, the cytoTBs aggregate, and by 48 h, they are clearly fused into multinucleated syncytia. The presence of human chorionic somatomammotropin (hCS) and chorionic gonadotropin (hCG) in the cells after 48 h was determined by immunohistochemistry. To assess whether hCS is synthesized in our cultures we examined hCS mRNA accumulation with time. The presence of hCS mRNA was detected at the time of plating but full length transcripts were seen only at later times indicating synthesis in culture. However, preparations at the time of plating contain fragments of syncytiotrophoblast (syncytioTB) generated by enzymic or mechanical disaggregation. These fragments could fuse with the cytoTBs. The inclusion of these fragments makes analysis of placental hormones by protein detection an unreliable assay for synthesis. Analysis of mRNA levels support hCS synthesis in culture and correlates with aggregation and fusion of cytoTBs. Thus, the fused cells in culture mimic the cellular site of hCS synthesis in vivo, the syncytioTB.

Enzymatic isolation of human trophoblast and culture on various substrates: comparison of first trimester with term trophoblast

A simple method is described for the isolation of trophoblast cells from both first trimester and term placenta. Trophoblast preparations were characterized by light microscopy, scanning and transmission election miscroscopy and immunohistochemistry to distinguish these cells from mesenchyme and endothelium. Trophoblast cells were cultured on various substrates and a comparison made of their ability to attach, proliferate and function. A collagen gel substrate produced by repolymerization of an acid soluble collagen fraction from chorionic villi allowed rapid attachment of trophoblast cells and maintainance of their original morphology. Term trophoblast cells were shown to become fully functional in short term (three day) cultures by virtue of their increased immunocytochemical staining for the presence of beta hCG, hPL and SPI. beta hCG increased significantly by day three thus demonstrating functional activation. Trophoblast cells from first trimester placenta formed proliferating colonies of hormone producing cells while those from term placenta reaggregated into clusters and closely resembled syncytiotrophoblast both morphologically and functionally. This short term culture system for term trophoblast will allow further studies into the biology of trophoblast polypeptide hormone synthesis and secretion.

Cyclic adenosine 3',5'-monophosphate analogues modulate rat placental cell growth and differentiation

Cyclic adenosine 3',5'-monophosphate (cAMP) has been implicated in the control of placental function. The present investigation was designed to evaluate the actions of cAMP analogues on the control of rat placental development. Two model systems were used to assess the actions of cAMP in the placenta: 1) a rat placental cell line and 2) rat labyrinth placental explants. Elevation of intracellular cAMP via treatment with cAMP analogues, 3-isobutyl-1-methylxanthine, forskolin, or cholera toxin inhibited placental cell DNA synthesis whereas treatment with an analogue to cyclic guanosine 3',5'-monophosphate was without effect. The inhibitory actions of dibutyryl cAMP on DNA synthesis were at least partially reversible and were not the result of metabolic toxicity. Dibutyryl cAMP had dramatic effects on the organization and morphology of placental cells growing in vitro and diminished the ability of the placental cells to grow following transplantation into allogeneic hosts. Differentiation-associated characteristics of rat placental cells were also affected by cAMP. cAMP analogues stimulated placental cell progesterone release and inhibited placental cell alkaline phosphatase activity. Dibutyryl cAMP had effects on placental labyrinth explants similar to its effects on the placental cell line. Dibutyryl cAMP inhibited explant outgrowth while stimulating explant release of progesterone. In summary, cAMP effectively modulates the growth and differentiation of rat placental cells in vitro.

[A histologic and functional evaluation of non-villous trophoblasts in the basal plate of human placenta]

This investigation of trophoblasts (Trs) in early gestation was performed by histologic and immunohistochemical evaluation of the Trs of the basal plate, decidua and myometrium, in an attempt to determine the changes in structure and function dependent on their location. The structural evaluation was performed by both light and electron microscopy and the functional evaluation by the localization of hCG, its subunits and hPL. In the syncytiotrophoblastic cell layer both hCG, its subunits and hPL are localized intracellularly. In the decidua, the so-called invasive Trs, only hPL could be detected. Histologically, the Trs in the deeper decidua tend to coalesce and become multinucleated. Thus, villous Trs and invasive Trs differ not only structurally, but also functionally, as can be seen by the differences in the synthesis of hCG and hPL, leading to the assumption that Trs have varying functions dependent upon their location.

Molecular cloning and expression of mouse placental lactogen I complementary deoxyribonucleic acid

The mouse midpregnancy lactogen or placental lactogen I (mPL-I) is encoded by a 1.0-kilobase mRNA that appears transiently during gestation, with maximal amounts accumulating in the placenta at day 10 of pregnancy. Several cDNA clones for mPL-I have been isolated from a lambda gt11 expression library constructed from day 10-placental RNA. The cDNA sequence indicates that mPL-I is synthesized as a 224 amino acid precursor, and is secreted as a 194 amino acid glycosylated hormone. The deduced amino acid sequence of mPL-I is highly homologous to the known members of the PRL family in the mouse, and hybridization analysis indicates that the mouse genome contains several mPL-I genes. Introduction of the mPL-I cDNA in an expression vector into cultured mouse cells results in the synthesis and secretion of glycosylated mPL-I protein that is recognized by anti-mPL-I antiserum and is biologically active.

Antifertility actions of the progesterone antagonist RU 486 include direct inhibition of placental hormone secretion

the antifertility effects of the potent antiprogestin RU 486 (mifepristone) during early pregnancy have been attributed to its blockade of progesterone receptors in the endometrium. Studies in cultured syncytiotrophoblasts have revealed an additional action of RU 486 at the placental level, where it impairs the production of human chorionic gonadotropin (hCG), human placental lactogen (hPL), and progesterone. RU 486 (10 nmol-10 mumol/l) attenuated the production of all three placental hormones, in a dose-related manner, and its effects on hCG and hPL were reversed by addition of exogenous progesterone. The specific inhibitory effects of RU 486 on placental hormone secretion indicate that its antifertility actions are attributable to competitive inhibition of progesterone action in the trophoblast as well as in the endometrium.

The effects of insulin-like growth factor-I and insulin on placental lactogen production by human term placental explants

The effects of insulin-like growth factor (IGF)-I and insulin on placental lactogen production (hPL) by term human placental explants were studied. The hPL content in medium and explant decreased rapidly after first 24 hours of culture. The decrease thereafter was gradual and reached a plateau by day 4 of culture. The decrease of HPL content in placental culture has previously been suggested being due to the depletion of a rapidly secreting preformed pool of hPL. Addition of IGF-I (0.1-10 micrograms/ml) and insulin (1-20 micrograms/ml) stimulated the decreased level of hPL in tissue and medium after 24 hours in culture. IGF-I was 10 times more potent than insulin in stimulating hPL. These findings suggest that IGF-I and insulin effects the production of hPL by placenta. The lower potency of insulin may indicate that the effect of insulin on hPL production is via IGF-I receptor.

Placental lactogen production and functional differentiation of rat trophoblast cells in vitro

Cells from the labyrinth region of the developing rat chorioallantoic placenta were able to differentiate in vitro into cells capable of producing placental lactogen. Progesterone selectively inhibited placental lactogen production by labyrinth cell cultures undergoing differentiation but had no apparent effect on lactogen production by mature trophoblast giant cells. The measurement of placental lactogen production is a useful method for monitoring the functional differentiation of rat trophoblast cells in vitro.

Detection of the mRNA to placental alkaline phosphatase by in vitro translation and immunoprecipitation

RNA prepared from human placental syncytiotrophoblast tissue was analysed by in vitro translation and immunoprecipitation. The major polypeptide synthesized from syncytiotrophoblast mRNA was human placental lactogen, accounting for 15-20 per cent of the translated polypeptides. Immunoprecipitation using antibodies to placental alkaline phosphatase (PLAP) specifically precipitated polypeptides of 56 kD and 58 kD. The possible relationship between these polypeptides and those of placental microvillus PLAP is discussed.

In vitro kinetics of synthesis and release of mouse placental lactogen

The dynamics of the in vitro synthesis and release of mouse placental proteins and mouse placental lactogen (mPL) were examined by culturing explants from mouse placentae from days 11, 14, and 17 of gestation for up to 24 h. The amount of mPL in medium and tissue was determined by RIA, and new protein synthesis was measured by the incorporation of [3H]leucine into mPL and proteins. The rate of synthesis of 3H-labeled proteins and [3H]mPL was constant for 17 h of incubation, confirming the viability of the placental tissue. Rapid and preferential release of newly synthesized mPL was observed; 88% of the mPL synthesized in 24 h was released into the medium, and the ratio of [3H]mPL to 3H-labeled proteins in the medium (14-18%) was significantly higher than that in the tissue (1-4%). There is not a stable storage pool of mPL under these conditions, as demonstrated by the similarity of the ratios of counts per min of [3H]mPL to nanograms of mPL in the medium and tissue. This conclusion is supported by the observed parallelism of mPL synthesis and release and the low tissue content of mPL. Release of mPL per mg tissue was similar for day 11 and day 14 placentae. It appears that mPL release in the absence of in vivo regulatory factors is strictly a function of placental mass at this time in gestation. A lower release from cultured day 17 placentae probably represents a decrease in the level of metabolic activity of the placenta as parturition approaches.

Sn-1,2-diacylglycerols and phorbol esters stimulate the synthesis and release of human placental lactogen from placental cells: a role for protein kinase C

Activation of calcium-stimulated phospholipid-dependent protein kinase C (PKC) by diacylglycerols and phorbol esters has been shown to mediate the release of secretory proteins in several systems. To determine whether PKC activation is involved in regulation of the release of human placental lactogen (hPL) from the placenta, we examined the effects of various acylglycerols and phorbol esters on the release of hPL from cultured human trophoblast cells. Sn-1,2-dioctanoylglycerol (diC8) and phorbol-12-myristate-13-acetate (PMA), both of which stimulate placental protein kinase C activity, caused dose-dependent increases in hPL release over a 0.5-h period. The maximal amounts of hPL released in response to diC8 (300 microM) and PMA (10(-8) M) were 200-300% and 150-225% greater, respectively, than that released in response to diluent alone. Acylglycerols and phorbol esters, which are less potent stimulators of PKC activity in other systems, stimulated hPL release to a lesser extent than either diC8 or PMA. PKC-inactive acylglycerols and phorbol esters were without effect. After 0.5 h of exposure, diC8 (300 microM)- and PMA (10(-8) M)-exposed cells synthesized 257.5% and 250.3% more hPL than control cells. Cycloheximide at a dose (50 micrograms/ml) that inhibited the synthesis of trichloroacetic acid-precipitable [35S]methionyl placental proteins by more than 80% completely blocked the stimulatory effects of diC8 and PMA on hPL synthesis and release. Although diC8 and PMA stimulated the synthesis and release of hPL, these compounds had no effect on the release of hCG and did not cause the release of the cytosolic enzymes lactic dehydrogenase and alkaline phosphatase. The demonstration that acylglycerols and phorbol esters stimulate the synthesis and release of hPL strongly implicates protein kinase C activation in the mechanisms of hPL synthesis and release.